Résumé
Levels of oxytocin [OXT] hormone and inflammatory biomarkers [leptin, resistin and adiponectin] were measured in 166 plasma samples of Metabolic Syndrome [MS] patients [1] that visited the outpatients' endocrinology clinics, Jordan University Hospital [JUH]. Patients were subdivided into two arms according to their glucose profile status, subjects with glucose profile disturbances and normoglycemic subjects. MS biomarkers were significantly different [P<0.01] between study groups, mean OXT levels [ng/mL] were exceptionally higher [p<0.01] in MS-control group [2.25+0.85] than in MS-pre/T2DM group [1.20+0.50]. Conversely, in comparison to MS-controls; MS-pre/T2DM patients had significantly higher adipocytokines plasma levels; namely resistin was 13 times higher [ng/mL] [82.05+ 32.44 vs. 6.45+4.39]; leptin two times higher [ng/mL] [42.43+30.44 vs. 22.76+14.19] and adiponectin was 3-fold higher [micro g/mL] [6.869+1.082 vs. 1.97+0.606]. These findings were indicative for the potential pharmacologic benefit of this hormone in minimization of inflammatory markers chronic deleterious effect